menu ☰
menu ˟

New adalimumab formulation associated with less injection site-related pain

20 Jul 2016
Results recently presented at the EULAR Annual Congress showed a new formulation of adalimumab at 40 mg/0.4 mL in the treatment of rheumatoid arthritis was associated with less injection site-related pain compared with the current formulation of adal...

Click here to view the full article which appeared in Rheumatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.